By Selina Lai, MS, Nutritionist In the past year there have been 2 investigative surveys of the lead content of protein powder supplements published by The Clean Label Project1 and […]
Nov. 26, 2025 Exciting news this week: Altay Therapeutics’ DX5057 has received Orphan Drug status from the U.S. FDA. DX5057 is currently the only oral DUX4 inhibitor in development for […]
− First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs) − The Phase 1/2a study will evaluate the safety and preliminary efficacy of […]
In October, our FSHD University hosted a webinar that explored how smart home technologies can transform daily life for people living with facioscapulohumeral muscular dystrophy (FSHD). Presented by community members […]
By Ranae Beeker, MSN, RN Written within the lens of awareness and the importance of respect. We understand that this topic is not of value to all of our community […]
English English 
العربية
Español de México
Français du Canada
简体中文
